Scanogen

Executive Summary

Scanogen is a U.S.-based diagnostics company focused on combating bloodstream infections (BSI) and sepsis through its proprietary SMART (Single Molecule And Rapid Tethering) technology. Unlike traditional blood culture methods that can take days, Scanogen's platform enables direct pathogen identification from whole blood in under two hours, potentially reducing time-to-appropriate therapy significantly. The lead product, SMART-ID BSI Assay, is designed to guide targeted antimicrobial treatment, addressing the critical unmet need for rapid sepsis diagnostics. Founded in 2008 and headquartered in Baltimore, the company operates in the high-growth point-of-care diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance Submission for SMART-ID BSI Assay40% success
• Q4 2026Clinical Validation Study Results Published50% success
• Q1 2026Series B or Strategic Partnership Announcement60% success